TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7915294

Group type: EXPERIMENTAL
Intervention: Somatostatin (250 micrograms/h for 48 hours following a bolus of 250 micrograms)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no somatostatin)
Number of subjects: 100
Study: 3202339

Group type: EXPERIMENTAL
Intervention: Spinal anaesthetic with 1.5 mg.kg‐1 prilocaine (RA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: General anaesthetic with 5 mg.kg‐1 thiopentone, dextromoramide, nitrous oxide and enflurane (GA)
Number of subjects: 35
Study: 11898007

Group type: EXPERIMENTAL
Intervention: Hazelnut allergens identified through SDS-PAGE and IgE immunoblotting
Number of subjects: 72

Group type: COMPARATOR
Intervention: Birch extract
Number of subjects: 72

Group type: COMPARATOR
Intervention: Roasted hazelnut
Number of subjects: 72

Group type: COMPARATOR
Intervention: Purified peach lipid-transfer protein (LTP)
Number of subjects: 72
Study: 30175930

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 40 mg plus chlorthalidone
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil 80 mg plus chlorthalidone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Chlorthalidone alone (Control)
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: Azilsartan medoxomil plus chlorthalidone
Number of subjects: 551

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 551
Study: 29933531

Group type: EXPERIMENTAL
Intervention: Sanhuangyilong decoction plus methotrexate (MTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methotrexate (MTX) only
Number of subjects: 0
Study: 24447649

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Rasagiline 6 mg/day
Number of subjects: 250

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 22551231

Group type: EXPERIMENTAL
Intervention: naltrexone
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: naltrexone and combined behavioral intervention (CBI)
Number of subjects: 1383

Group type: EXPERIMENTAL
Intervention: acamprosate and CBI
Number of subjects: 1383
Study: 19968804

Group type: EXPERIMENTAL
Intervention: Raised ambient temperature (26 degrees C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard ambient temperature (21 degrees C)
Number of subjects: 60
Study: 18534287

Group type: EXPERIMENTAL
Intervention: Thymosin alpha 1 (Talpha1)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 73
Study: 15989416

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Sit-up exercises
Number of subjects: 72

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 72
Study: 12798519

Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (between 72 and 120 hours)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Yuzpe regimen (within 72 hours)
Number of subjects: 111
Study: 10482480

Group type: EXPERIMENTAL
Intervention: Ciclosporin microemulsion preconcentrate (MEPC)
Number of subjects: 47
Study: 8739805

Group type: EXPERIMENTAL
Intervention: Selegiline monotherapy
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1750727

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg b.i.d.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: terfenadine 120 mg b.i.d.
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15
Study: 6751366

Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline 350 mg daily for 4 days followed by 700 mg daily for 4 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Matching placebo tablets for 8 days
Number of subjects: 21
Study: 30509740

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks intravenously
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard of care (methotrexate, docetaxel, or cetuximab)
Number of subjects: 495

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 495

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 495
Study: 29282470

Group type: EXPERIMENTAL
Intervention: Active tDCS (10 daily 30-minute, 2-mA sessions)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 59
Study: 26740484

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen therapy
Number of subjects: 441
Study: 24488324

Group type: EXPERIMENTAL
Intervention: Icotinib 400 mg with high-fat and high-calorie meal
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Icotinib (dose range 100-600 mg)
Number of subjects: 22
Study: 22156624

Group type: EXPERIMENTAL
Intervention: Consolidation docetaxel (D; Taxotere) after EP/XRT
Number of subjects: 243

Group type: COMPARATOR
Intervention: Observation (O)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: EP/XRT (cisplatin and etoposide with concurrent chest radiation)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Older patients (≥ 70 years)
Number of subjects: 243
Study: 20937567

Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 16685703

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15869669

Group type: EXPERIMENTAL
Intervention: Right-sided VDD implantation
Number of subjects: 82

Group type: COMPARATOR
Intervention: Left-sided VDD implantation
Number of subjects: 82
Study: 11986603

Group type: EXPERIMENTAL
Intervention: Non-heparin-bonded circuits with cardiotomy suction (group I)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits with cardiotomy suction (group II)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heparin-bonded circuits without cardiotomy suction (group III)
Number of subjects: 36
Study: 9706319

Group type: EXPERIMENTAL
Intervention: Social-cognitive group intervention (ten, 2-hour weekly sessions)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Comparison of drug/alcohol users and nonusers, fighters and nonfighters, and students threatened at school and those not threatened
Number of subjects: 50
Study: 7618676

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg by bolus injection followed by infusion (5 mg.h‐1 for 12 h and 2.5 mg.h‐1 for a further 12 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg by bolus injection followed by infusion (10 mg.h‐1 for 12 h and 5 mg.h‐1 for a further 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine sulphate 2 mg by bolus injection followed by infusion (0.2 mg.h‐1 for 12 h and at 0.1 mg.h‐1 for further 12 h)
Number of subjects: 12
Study: 2616934

Group type: EXPERIMENTAL
Intervention: Treatment A (specific treatment not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment B (specific treatment not mentioned)
Number of subjects: 0
Study: 339343

Group type: EXPERIMENTAL
Intervention: Na2FPO3 containing toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30319034

Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the entire video (complete)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the traumatic (central) details of the event only (trauma‐focused)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeatedly recalled the non‐traumatic (peripheral) details of the event only (non‐trauma focused)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No recall at all (no‐recall control)
Number of subjects: 0
Study: 28750828

Group type: EXPERIMENTAL
Intervention: Alirocumab (75/150 mg every 2 weeks)
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 720

Group type: COMPARATOR
Intervention: Ezetimibe
Number of subjects: 720
Study: 26712972

Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg (Group O, n = 32)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: glycopyrrolate 0.2 mg (Group G, n = 31)
Number of subjects: 66
Study: 24326013

Group type: EXPERIMENTAL
Intervention: Flexible spiral wire retainer
Number of subjects: 142

Group type: COMPARATOR
Intervention: Polyethylene woven ribbon retainer
Number of subjects: 142
Study: 21606291

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation-based training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Didactic lecture
Number of subjects: 44
Study: 19421167

Group type: EXPERIMENTAL
Intervention: CYP2D6 score (0 to 2 based on predicted allele activities)
Number of subjects: 297
Study: 16846819

Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation (ETS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medications
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Acupressure and Acupuncture
Number of subjects: 12
Study: 15273005

Group type: EXPERIMENTAL
Intervention: Positive mood induction without external attribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative mood induction without external attribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: External attribution provided (for both positive and negative mood induction)
Number of subjects: 0
Study: 11339442

Group type: EXPERIMENTAL
Intervention: 250 microg folic acid daily
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: 500 microg folic acid daily
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 9148986

Group type: EXPERIMENTAL
Intervention: Diagnostic peritoneal lavage (DPL) with 1 L crystalloid
Number of subjects: 11
Study: 8131364

Group type: EXPERIMENTAL
Intervention: Natural surfactant extract (prophylactic administration)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Natural surfactant extract (administration to infants with moderate to severe RDS)
Number of subjects: 2500
Study: 3693585

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 19
Study: 31352308

Group type: EXPERIMENTAL
Intervention: LINK LA peer navigation intervention
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: High-risk drug use (methamphetamine, cocaine, opioids)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 356
Study: 30097052

Group type: EXPERIMENTAL
Intervention: Bayview site without mask
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bayview site with mask
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exposure to CO, UFP, and SO2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayview site exposures
Number of subjects: 0
Study: 26741306

Group type: EXPERIMENTAL
Intervention: Anterior mini-implant group (AMG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Posterior mini-implant group (PMG)
Number of subjects: 32
Study: 25146296

Group type: EXPERIMENTAL
Intervention: Criticisms of the state, its leaders, and their policies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Posts about real-world events with collective action potential
Number of subjects: 0
Study: 22527337

Group type: EXPERIMENTAL
Intervention: Cement injection stem (secondary cementing technique)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cemented stem (primary cementing technique)
Number of subjects: 30
Study: 19326803

Group type: EXPERIMENTAL
Intervention: Multidisciplinary quality improvement program to reduce RFOs, including education programs, team training, simulation videos, and daily reminders.
Number of subjects: 0
Study: 17846974

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15327636

Group type: EXPERIMENTAL
Intervention: Training procedure to manipulate the strength of associations between pairs of words
Number of subjects: 0
Study: 11075845

Group type: EXPERIMENTAL
Intervention: Intranasal civamide 20 microg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intranasal civamide 150 microg
Number of subjects: 34
Study: 8938011

Group type: EXPERIMENTAL
Intervention: Auditory detection during saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitch discrimination during saccades
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auditory localisation during saccades
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory detection during periods of fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pitch discrimination during periods of fixation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory localisation during periods of fixation
Number of subjects: 0
Study: 1411248

Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 85
Study: 4073084

Group type: EXPERIMENTAL
Intervention: ticarcillin plus clavulanic acid
Number of subjects: 93

Group type: COMPARATOR
Intervention: cefoxitin
Number of subjects: 93
Study: 3732891

Group type: EXPERIMENTAL
Intervention: Whole gut irrigation and 5-aminosalicylic acid
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conservative treatment (total parenteral nutrition and steroids)
Number of subjects: 18
Study: 31659822

Group type: EXPERIMENTAL
Intervention: iCBT (internet-delivered cognitive behavioural therapy)
Number of subjects: 114

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 114
Study: 29059146

Group type: EXPERIMENTAL
Intervention: HA-RK
Number of subjects: 60

Group type: COMPARATOR
Intervention: HA-JV
Number of subjects: 60
Study: 29122230

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation program (10 sessions)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no cognitive stimulation)
Number of subjects: 37
Study: 26231624

Group type: EXPERIMENTAL
Intervention: Home CIMT
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 156
Study: 23279658

Group type: EXPERIMENTAL
Intervention: Intradiscal biacuplasty (IDB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 59
Study: 21930607

Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 75

Group type: COMPARATOR
Intervention: Hyperimmune bovine colostrum (HIBC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Raltegravir + HIBC
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 75
Study: 18327413

Group type: EXPERIMENTAL
Intervention: Venowave
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control device
Number of subjects: 32
Study: 16291600

Group type: EXPERIMENTAL
Intervention: 90 mg etoricoxib once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 25 mg rofecoxib once daily
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 102
Study: 12603638

Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 1334

Group type: EXPERIMENTAL
Intervention: Eletriptan 80 mg
Number of subjects: 1334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1334
Study: 10924983

Group type: EXPERIMENTAL
Intervention: Extended tangents technique
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 5-field technique
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Partly wide tangents technique
Number of subjects: 5

Group type: COMPARATOR
Intervention: Supraclavicular field matched to standard tangential fields
Number of subjects: 5
Study: 9356095

Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation without airway endoscopy mask
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Fiberoptic intubation with airway endoscopy mask
Number of subjects: 144

Group type: COMPARATOR
Intervention: Laryngoscopic intubation
Number of subjects: 144
Study: 8229492

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance of suprapubic bladder aspiration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unguided aspiration
Number of subjects: 0
Study: 3710013

Group type: EXPERIMENTAL
Intervention: Sucrose diet (45 g of sucrose replacing 45 g of complex carbohydrate)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control diet (high in fibre and low in fat)
Number of subjects: 23
Study: 29803703

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: ALPS treatment group
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Rearrest
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: ECG waveform characteristics
Number of subjects: 1144
Study: 27723781

Group type: EXPERIMENTAL
Intervention: Dance (n = 50)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Walking (n = 108)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Strength/Stretching/Stability (SSS; n = 48)
Number of subjects: 195
Study: 24359506

Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Risperidone 4 mg daily
Number of subjects: 45
Study: 22260988

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (one, two, or three doses at 1 month, 2 months, or 6 months intervals)
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (two or three doses)
Number of subjects: 1631

Group type: EXPERIMENTAL
Intervention: 4CMenB vaccine (second or third doses)
Number of subjects: 1631

Group type: COMPARATOR
Intervention: 4CMenB vaccine
Number of subjects: 1631

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1631
Study: 20377741

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Subcutaneous (SC) injection
Number of subjects: 120
Study: 17904629

Group type: EXPERIMENTAL
Intervention: Treatment (phone- and mail-based physical activity maintenance intervention)
Number of subjects: 1049

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1049
Study: 17265699

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 12534644

Group type: EXPERIMENTAL
Intervention: Erythromycin (600 mg ethylsuccinate ester, three oral doses on day 1 and two doses on day 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Erythromycin (in patients with Child's grade C liver cirrhosis)
Number of subjects: 30
Study: 10987609

Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9120119

Group type: EXPERIMENTAL
Intervention: Gastric air tonometry
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline tonometry
Number of subjects: 20
Study: 1460168

Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation with RS 86
Number of subjects: 90
Study: 3883182

Group type: EXPERIMENTAL
Intervention: Omeprazole (30 mg per day)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Cimetidine (1 g per day)
Number of subjects: 132
Study: 31758080

Group type: EXPERIMENTAL
Intervention: Chemotherapy (specific regimen not detailed)
Number of subjects: 0
Study: 27806879

Group type: EXPERIMENTAL
Intervention: Snake algorithm applied to subjects with carotid plaques
Number of subjects: 44
Study: 27012848

Group type: EXPERIMENTAL
Intervention: Intervention (phone- and web-based weight loss program)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 105
Study: 25082605

Group type: EXPERIMENTAL
Intervention: Intervention (monthly telephone interviews for six months)
Number of subjects: 914

Group type: COMPARATOR
Intervention: Usual care (telephone interviews at three and six months)
Number of subjects: 914
Study: 22963503

Group type: EXPERIMENTAL
Intervention: 2.0 mA tDCS
Number of subjects: 19

Group type: COMPARATOR
Intervention: 0.1 mA tDCS
Number of subjects: 19
Study: 18948032

Group type: EXPERIMENTAL
Intervention: EPO (epoetin alfa, 500 IU/kg intravenously)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 17886412

Group type: EXPERIMENTAL
Intervention: Social interactions perceived as helpful (n=7)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Social interactions perceived as unhelpful (n=7)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Social interactions perceived as both helpful and unhelpful (n=6)
Number of subjects: 22
Study: 15039493

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11257953

Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg every 8 h
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg every 8 h
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 104
Study: 9777899

Group type: EXPERIMENTAL
Intervention: Targeted, multi‐component disability prevention and disease self‐management program led by a geriatric nurse practitioner (GNP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 7870226

Group type: EXPERIMENTAL
Intervention: Normal Hemodialysis (NHD) at 36.5 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Warm Hemodialysis (WHD) at 38.5 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold Hemodialysis (CHD) at 34.5 degrees C
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All dialysate temperatures
Number of subjects: 10
Study: 3346792

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.125 mg/kg intravenous dose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.125 mg/kg four times a day for 24 hours)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 28
Study: 31157710

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) plus peripheral ischemic retinal photocoagulation
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) alone
Number of subjects: 48